awmsg logo



emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®)


Reference No. 3031

Publication date:
21/11/2016


Appraisal information

emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®) 200mg/25mg/25mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 05/10/2016
AWMSG meeting date: 09/11/2016
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 3316
Ministerial ratification: 18/11/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Emtricitabine/rilpivirine/tenofovir alafenamide (Odefsey®) is recommended as an option for use within NHS Wales for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus-1 (HIV-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV-1 RNA copies/ml.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download